These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 26125128)

  • 1. Potential therapeutic targets in ARID1A-mutated cancers.
    Bitler BG; Fatkhutdinov N; Zhang R
    Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
    Bitler BG; Aird KM; Garipov A; Li H; Amatangelo M; Kossenkov AV; Schultz DC; Liu Q; Shih IeM; Conejo-Garcia JR; Speicher DW; Zhang R
    Nat Med; 2015 Mar; 21(3):231-8. PubMed ID: 25686104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
    Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
    Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
    Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
    Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
    Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R
    Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting ARID1A mutations in cancer.
    Mullen J; Kato S; Sicklick JK; Kurzrock R
    Cancer Treat Rev; 2021 Nov; 100():102287. PubMed ID: 34619527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
    PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARID1A loss in cancer: Towards a mechanistic understanding.
    Mathur R
    Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations.
    Bitler BG; Aird KM; Zhang R
    Mol Cell Oncol; 2016 Jan; 3(1):e1032476. PubMed ID: 27308548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
    Li S; Meersma GJ; Kupryjanczyk J; de Jong S; Wisman GBA
    J Transl Med; 2024 Jun; 22(1):556. PubMed ID: 38858765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
    Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
    Elife; 2017 Oct; 6():. PubMed ID: 28967863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
    Mandal J; Mandal P; Wang TL; Shih IM
    J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
    Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
    Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of the AT-Rich Interaction Domain 1A Gene (
    Li JJ; Lee CS
    Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.